BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.2M data for 1.4M Compounds and 11.4K Targets. Of those, 1.6M data for 748K Compounds and 4.8K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

Advanced Search

21 articles for I Mochalkin

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Exploration of 4,4-disubstituted pyrrolidine-1,2-dicarboxamides as potent, orally active Factor Xa inhibitors with extended duration of action.EBI
Pfizer
Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered Cancers.EBI
Emd Serono Research & Development Institute
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors.EBI
Emd Serono Research and Development Institute
Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases.EBI
Merck
Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.EBI
Pfizer
Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.EBI
Emd Serono Research & Development Institute
Optimization of the efflux ratio and permeability of covalent irreversible BTK inhibitors.EBI
Emd Serono Research & Development Institute
Discovery of potent, highly selective covalent irreversible BTK inhibitors from a fragment hit.EBI
Emd Serono Research & Development Institute
Recent progress towards clinically relevant ATP-competitive Akt inhibitors.EBI
Merck
Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereofBDB
Ocuterra Therapeutics
Heteroaryl inhibitors of PAD4BDB
Padlock Therapeutics
ASK1 inhibitor and preparation method and use thereofBDB
Fuijan Cosunter Pharmaceutical
Compounds as inhibitors of DNA methyltransferasesBDB
FundaciÓN Para La InvestigaciÓN MÉDica Aplicada
Pyridyl analogs of 1-(2-cyano-3,12-dioxooleana-1,9(11)dien-28-oyl) imidazoleBDB
Dartmouth College
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDHBDB
Novartis
Inhibitors of SYKBDB
Hoffmann-La Roche
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitorsBDB
Novartis
Substituted [1,2,4]triazolo[4,3-a]pyrazines as PARP-1 inhibitorsBDB
Shanghai Institute of Material Medica, Chinese Academy of Sciences
Pyrimidooxazocine derivatives as mTOR-inhibitorsBDB
Sanofi
Benzoxazepin compounds selective for PI3K P110 delta and methods of useBDB
Genentech
Cyclic inhibitors of 11BETA-hydroxysteroid dehydrogenase 1BDB
Vitae Pharmaceuticals